Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cancer Care Delivery in Low Resource Environments
Breast Cancer
Presenter Shima Pashaei
Citation Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426
Authors S. Pashaei1, R. Dolatkhah1, Z. Sanaat2, P. Jabbaripour1, G.H. de Bock3
  • 1Tabriz University Of Medical Sciences, Hematology and Onclogy Research Center, 5166614731 - Tabriz/IR
  • 2Internal Medicine Department Hematology & Oncology, Shahid Ghazi Medical Center,Tabriz University of Medical Sciences, 51656 - Tabriz/IR
  • 3University Medical Center, Oncological Epidemiology, 57468936541 - Groningen/NL



Historically, breast cancer (BC) incidence and survival in middle income countries are lower than in developed countries. The aim of this study was to provide recent data on the BC incidence and survival in Iran.


Data of the patients diagnosed with confirmed BC as registered in the East Azerbaijan cancer registry between 2011 and 2015 were linked to the regional death registration system. The 5 year age standardized incidence rates (ASIRs) for BC were estimated. With Kaplan Meier methods, the BC specific one and five year survival rates were estimated.


There were 2,677 patients diagnosed with breast cancer, 97.6% (n = 2612) were female, with a mean age of 51 of years (SD: 13.28). Over the study period, the ASIRs increased from 1.08 to 16.12 per 100,000. The one and five year BC specific survival rates were 96.5%, 59.3%, respectively.


We observed a sharp increase in incidence BC, which might be explained by the improvement of compliance to the cancer registration. Survival rates are still low compared to western countries.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Hematology and Oncology Reserach Center.


Has not received any funding.


All authors have declared no conflicts of interest.